In this week’s Innovation Partners BioBlog, we look at several top stories from the pharmaceutical industry. Merck is testing machine learning to predict demand, a move that is expected to prevent wasteful stockpiling and expired drugs. Pfizer fills the gap left by Teva’s discontinuation of an important cancer-fighting drug often used for children’s cancers. Several reports examine the impact of the House Speaker Pelosi’s proposal to lower the cost of drugs and its potential impact on the pharmaceutical industry. Read more for the top stories in this week’s Innovation Partners BioBlog.
School of Pharmaceutical & Biotech Business
10.29.19 Scottsdale, AZ
This program will give pharmaceutical and biotechnology professionals the rare opportunity to view the oncology space, its future and its current operational issues from the provider, advocacy, and payer perspectives.
NCCN Academy for Excellence & Leadership in Oncology – School of Pharmaceutical & Biotech Business will take place on Tuesday, October 29 at The Phoenician in Scottsdale, Arizona.
To counteract periodic drug shortages, German pharmaceutical company Merck is testing machine learning for global forecasting. Machine learning uses data to help computers “learn” and make reasonable, logical predictions based on massive amounts of data. Drugmakers typically stockpile medications in anticipation of peak demand but this is inefficient and often leads to expired medications. Merck’s forecasting to date has been 85% accurate using the new system. TraceLink is developing the pilot platform specifically for Merck KGaA’s immuno-oncology business.
The administration hopes that the new executive order signed by President Trump ushers in an era of consumer choice and price comparison in medicine. The new executive order mandates that healthcare providers publish the cost of medical procedures before consumers receive them. Traditionally, consumers have received bills only after procedures are complete, leading to surprise bills and ‘sticker shock’ at the costs of services. The new order, if enforced, will ensure that consumers know the price charged, what their insurance pays, and what, if any, out of pocket costs they will incur.
An analysis by the Congressional Budget Office found that House Speaker Nancy Pelosi’s drug prices plan would reduce Medicare spending by $345 billion over a seven-year period but could impact the number of new drugs potentially entering the market. The bill would give Medicare the power to negotiate lower drug prices, which would save money on Medicare Part D. Negotiated Medicare drug prices would also be required to be offered to commercial plans. The plan came about to force companies to offer drugs in the United States at the same prices paid by other nations. The fear is that companies might pull out of the U.S. market if prices drop.
Medicare Part D beneficiaries may see an increase in their out of pocket costs next year before they hit the catastrophic threshold. The Kaiser Family Foundation looked at how policy changes might impact Medicare Part D and found that the catastrophic threshold for 2020 will rise from $5,100 to $6,350. This represents a 25% increase. Beneficiaries who take only brand-name drugs will pay for a quarter of that increase out of their pockets, while the rest will be covered by drugmaker discounts. Beneficiaries who take only generic drugs will pay the entire increase out of pocket.
Pfizer is trying to fill the gap created when Teva Pharmaceuticals discontinued the manufacturing of vincristine, a drug often used to treat children with brain tumors, leukemia, and lymphoma. Vincristine is so widely used that the shortage is affecting both patients and clinical trials. Teva claims that its decision to leave the market was not the cause of the shortage. It said that based on data from 2017, the company found its share of the market was never more than 15% and was a little as 3% per month on average this year.
A recent study from the Pacific Research Institute found that every state would receive significant savings in its Medicare programs if it expanded the use of biosimilars instead of the more expensive biologics. Biologics have no meaningful difference in terms of safety or effectiveness compared to its originator biologic medication. Generic medications, on the other hand, are chemically identical versions of a branded medication. Biosimilars currently save the healthcare system $240.4 million. Of these savings, 19.8% is realized by state Medicaid programs and 56.9% by the commercial market.